Registry for patients with advanced metastatic breast cancer in Southeast Netherlands

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Southeast Netherlands Advanced Breast Cancer Registry (SONABRE) is an observational cohort study that aims to include all patients diagnosed with advanced breast cancer since 2007 across 11 hospitals in the Southeast Netherlands. Trained clerks collect retrospective data from electronic medical records, focusing on patient demographics, tumor characteristics, treatment modalities, and outcomes. This registry facilitates real-life studies on the safety and effectiveness of various systemic treatments for advanced breast cancer. The data collected will help improve understanding and management of this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with de novo or recurrent advanced breast cancer since 2007
* Diagnosed with or treated for advanced breast cancer in one of the participating hospitals
* Participating hospitals (period of inclusion): Maastricht UMC+ (2007-2025), Zuyderland hospitals Sittard/Heerlen (2007-2025), Amphia Hospital Breda (2013-2025), Catharina Hospital Eindhoven (2007-2025), Elkerliek Hospital Helmond (2010-2025), Maxima Medical Center Veldhoven/Eindhoven (2007-2025), Jeroen Bosch Hospital Den Bosch (2013-2025), Laurentius Hospital Roermond (2007-2025), St. Annaziekenhuis Geldrop (2007-2025), St. Elisabeth Hospital Tilburg (2007-2009), St. Jans Gasthuis Weert (2007-2025), VieCuri Medical Center Venlo/Venray (2013-2025), all in the Netherlands.
* Hospitals (and periods) were eligible for inclusion if (distant) registration from Maastricht UMC+ was possible.
* The inclusion period may be prolonged after 2025.

Exclusion Criteria: none

Where it's running

• Multiple hospitals in the Netherlands (see Eligibility)
  Maastricht, Netherlands Recruiting

Study contacts

• Study coordinator: Vivianne CG Tjan-Heijnen, MD, PhD
• Email: vcg.tjan.heijnen@mumc.nl
• Phone: +31 (0) 43 3877025

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• T-DXd–based therapy followed by targeted HER2 blockade and endocrine therapy in first-line HER2+ / HR+ metastatic breast cancer

  This trial tests a sequence of therapies starting with T-DXd plus pertuzumab, then a maintenance phase with dual HER2 blockade, endocrine therapy, and CDK4/6 inhibitor, with a retreatment option of T-DXd if disease progresses.

  Recruiting at 5 sites Phase 3 Daiichi Sankyo · Columbia, Maryland and 4 other locations · NCT07683754

• Capivasertib plus endocrine therapy for HR+/HER2- advanced breast cancer after progression on endocrine treatment

  This trial will test whether adding capivasertib to standard endocrine therapy helps adults with HR+/HER2- advanced or metastatic breast cancer who progressed on prior endocrine treatment stay on treatment longer and maintain quality of life.

  Recruiting at 15 sites Phase 3 Women's Cancer Study Group GmbH · Anderlecht and 15 other locations · NCT07281833

• TheraBionic P1 device in advanced HR-positive, HER2-negative breast cancer

  This trial tests whether the TheraBionic P1 device can help women with advanced or metastatic HR-positive, HER2-negative breast cancer who have progressed on standard therapies, by looking at survival and disease control.

  Recruiting at 8 sites Barbara Ann Karmanos Cancer Institute · Bay City, Michigan and 7 other locations · NCT07227831

• RLY-2608 plus fulvestrant versus capivasertib plus fulvestrant for PIK3CA‑mutant HR+/HER2‑ advanced breast cancer

  This trial tests whether RLY-2608 combined with fulvestrant works better than capivasertib combined with fulvestrant for adults with HR+/HER2‑ advanced breast cancer that has a PIK3CA mutation and progressed after a CDK4/6 inhibitor.

  Recruiting at 254 sites Phase 3 Relay Therapeutics, Inc. · Gilbert, Arizona and 253 other locations · NCT06982521

• Testing new antibody drugs in advanced breast cancer patients who have used similar treatments before

  This study is testing new antibody drugs to see if they can help advanced breast cancer patients who have already tried similar treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06649331

• Evaluating BBO-10203 for advanced solid tumors

  This study is testing a new treatment called BBO-10203, alone and with another drug, to see if it can help people with advanced solid tumors, including certain types of breast cancer.

  Recruiting at 43 sites Phase 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Duarte, California and 43 other locations · NCT06625775

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.